EA200701071A1 - Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака - Google Patents

Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака

Info

Publication number
EA200701071A1
EA200701071A1 EA200701071A EA200701071A EA200701071A1 EA 200701071 A1 EA200701071 A1 EA 200701071A1 EA 200701071 A EA200701071 A EA 200701071A EA 200701071 A EA200701071 A EA 200701071A EA 200701071 A1 EA200701071 A1 EA 200701071A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
relates
present
treatment
receptor
Prior art date
Application number
EA200701071A
Other languages
English (en)
Other versions
EA012072B1 (ru
Inventor
Хосе Энрике Монтеро Касимиро
Ливан Бладимир Алонсо Сардуи
Роландо Перес Родригес
Агустин Бьенвенидо Лаге Давила
Original Assignee
Сентро Де Инмунология Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентро Де Инмунология Молекулар filed Critical Сентро Де Инмунология Молекулар
Publication of EA200701071A1 publication Critical patent/EA200701071A1/ru
Publication of EA012072B1 publication Critical patent/EA012072B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение связано с фармацевтическими композициями, основанными на вакцинах и моноклональных антителах, которые нейтрализуют интерлейкин-2 и которые являются пригодными для лечения опухолей. В частности настоящее изобретение связано с терапевтическими композициями, способными повышать иммуногенность IL-2, присоединенного к белку-носителю P64k из Neisseria Meningitidis в адъюванте Montanide ISA 51, для индукции нейтрализующих IL-2 аутоантител, а также с эффективными способами лечения опухолей, включая рак молочной железы и меланому. Кроме того, настоящее изобретение связано с терапевтической комбинацией вакцины, основанной на IL-2, с другими противораковыми вакцинами, основанными на специфичных опухолевых антигенах или факторах роста опухоли, а так же химиотерапевтических агентах или радиотерапии стандартного использования для лечения рака.
EA200701071A 2004-11-16 2005-11-16 Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором, и их использование в лечении рака EA012072B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
PCT/CU2005/000009 WO2006053508A1 (es) 2004-11-16 2005-11-16 Formulaciones inmunoterapeuticas con capacidad neutralizante de la interleucina-2.

Publications (2)

Publication Number Publication Date
EA200701071A1 true EA200701071A1 (ru) 2007-12-28
EA012072B1 EA012072B1 (ru) 2009-08-28

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701071A EA012072B1 (ru) 2004-11-16 2005-11-16 Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором, и их использование в лечении рака

Country Status (25)

Country Link
US (1) US20090274647A1 (ru)
EP (2) EP2112160B1 (ru)
JP (1) JP5227028B2 (ru)
KR (1) KR101240457B1 (ru)
CN (1) CN101061136B (ru)
AR (1) AR051494A1 (ru)
AT (1) ATE525393T1 (ru)
AU (1) AU2005306186B2 (ru)
BR (1) BRPI0518007A (ru)
CA (1) CA2588573C (ru)
CR (1) CR9097A (ru)
CU (1) CU23297A1 (ru)
EA (1) EA012072B1 (ru)
GE (1) GEP20105039B (ru)
HK (1) HK1113374A1 (ru)
MA (1) MA29044B1 (ru)
MX (1) MX2007005808A (ru)
MY (1) MY162106A (ru)
PE (1) PE20061172A1 (ru)
SG (1) SG122897A1 (ru)
TN (1) TNSN07187A1 (ru)
TR (1) TR200704213T2 (ru)
TW (1) TWI433853B (ru)
WO (1) WO2006053508A1 (ru)
ZA (1) ZA200703528B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
TW201722989A (zh) 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
CU20210021A7 (es) * 2021-03-30 2022-11-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
JPS59116231A (ja) * 1982-12-13 1984-07-05 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 抗−インタ−ロイキン−２単クロ−ン抗体
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
MXPA01008110A (es) * 1999-02-12 2002-10-23 Scripps Research Inst Metodos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias anti-angiogenicas e inmunoterapia.
AU2001259253A1 (en) * 2000-04-26 2001-11-07 National Jewish Medical And Research Center Product and process for regulation of t cell responses
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (de) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Il2-peptide; von interleukin 2 abgeleitete peptide und peptid-dimere
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ITMI20012527A1 (it) * 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
CA2468258C (en) * 2001-11-30 2011-10-11 Jeffrey Schlom Peptide agonists of prostate-specific antigen, and uses therefor
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides

Also Published As

Publication number Publication date
CR9097A (es) 2007-08-28
EA012072B1 (ru) 2009-08-28
PE20061172A1 (es) 2006-12-16
SG122897A1 (en) 2006-06-29
CU23297A1 (es) 2008-07-24
KR20070084025A (ko) 2007-08-24
AR051494A1 (es) 2007-01-17
TNSN07187A1 (en) 2008-11-21
KR101240457B1 (ko) 2013-03-08
TR200704213T2 (tr) 2007-08-21
HK1113374A1 (en) 2008-10-03
EP2112160B1 (en) 2015-07-08
EP1829893A1 (en) 2007-09-05
TWI433853B (zh) 2014-04-11
MA29044B1 (fr) 2007-11-01
WO2006053508A1 (es) 2006-05-26
ATE525393T1 (de) 2011-10-15
EP1829893B1 (en) 2011-09-21
CA2588573C (en) 2013-12-31
ZA200703528B (en) 2008-06-25
US20090274647A1 (en) 2009-11-05
CA2588573A1 (en) 2006-05-26
GEP20105039B (en) 2010-07-12
MY162106A (en) 2017-05-31
EP2112160A3 (en) 2010-01-13
CN101061136B (zh) 2012-12-05
EP2112160A2 (en) 2009-10-28
JP2008526686A (ja) 2008-07-24
MX2007005808A (es) 2007-07-20
TW200631591A (en) 2006-09-16
AU2005306186B2 (en) 2012-05-31
CN101061136A (zh) 2007-10-24
BRPI0518007A (pt) 2008-10-21
JP5227028B2 (ja) 2013-07-03
AU2005306186A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
EA202191027A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
PH12018502250A1 (en) Cancer immunotherapy by immune activation for immune modulation via globo series antigens
Wiedermann et al. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
EA200300092A1 (ru) Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
MY157372A (en) Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
EA200701071A1 (ru) Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
MD3236985T2 (ro) Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor cancere
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
Talebi et al. Immuno-stimulating peptide derived from HMGB1 is more effective than the N-terminal domain of Gp96 as an endogenous adjuvant for improvement of protein vaccines
TH83896A (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2 เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
MY195821A (en) Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers
TH83896B (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
UY29216A1 (es) Formulaciones inmunoterapeúticas para la inducción de autoanticuerpos bloqueadores de la unión de interleucina-2 a su receptor. su uso en el tratamiento del cáncer
DE60325586D1 (de) Mycobakterielle Proteinantigene für Krebstherapie und Impfung
Helwick Breast Cancer Vaccines Moving Forward at a Fast Clip
TH138998A (th) Cdca5 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KZ MD

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU